ACCORD Lipid Flashcards
1
Q
ACCORD Lipid Clinical Q
A
Among adults with T2DM on statin monotherapy, does addition of a fibrate reduce risk of CVD?
2
Q
ACCORD Lipid Bottom Line
A
Among adults with T2DM on statin monotherapy, the addition of fenofibrate does not reduce CVD endpoints.
3
Q
ACCORD Lipid Primary outcome
A
First nonfatal MI, nonfatal stroke, or CVD mortality
4
Q
ACCORD Lipid Interventions
A
- This was a 2x2 factorial substudy (n=5,518) of the ACCORD study (n=10,251). All participants in ACCORD Lipid were also included in the Hgb A1c-targeted therapy of the main ACCORD study.
- In ACCORD Lipid, participants were randomized to a group:
- —Fenofibrate - Fenofibrate 160 mg/day, this became GFR-dose adjusted starting in 2004
- —Placebo
- All participants received simvastatin 20-40 mg/day
5
Q
ACCORD Lipid
A
There was heterogeneity in lipid profiles of participants. Those with high triglycerides and low HDL may have benefited.
